These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 28664852)

  • 1. Reappraisal of the clinical effect of mepolizumab.
    Lipworth BJ; Jabbal S
    Lancet Respir Med; 2017 Jun; 5(6):e20. PubMed ID: 28664852
    [No Abstract]   [Full Text] [Related]  

  • 2. Mepolizumab for Eosinophilic COPD.
    Sciurba FC; Bradford ES; Pavord ID
    N Engl J Med; 2018 Feb; 378(7):681-683. PubMed ID: 29443666
    [No Abstract]   [Full Text] [Related]  

  • 3. Mepolizumab for Eosinophilic COPD.
    Xia Y; Li W; Shen H
    N Engl J Med; 2018 Feb; 378(7):680-1. PubMed ID: 29446291
    [No Abstract]   [Full Text] [Related]  

  • 4. Mepolizumab for Eosinophilic COPD.
    Shahlavi‑Monavvar P; Mobasher-Jannat A
    N Engl J Med; 2018 Feb; 378(7):681. PubMed ID: 29446292
    [No Abstract]   [Full Text] [Related]  

  • 5. Severe eosinophilic asthma and mepolizumab.
    Walsh GM
    Lancet Respir Med; 2016 Jul; 4(7):528-529. PubMed ID: 27177492
    [No Abstract]   [Full Text] [Related]  

  • 6. Mepolizumab, quality of life, and severe eosinophilic asthma.
    Pavord ID
    Lancet Respir Med; 2017 May; 5(5):362-363. PubMed ID: 28395935
    [No Abstract]   [Full Text] [Related]  

  • 7. Mepolizumab: A Review in Eosinophilic Asthma.
    Deeks ED
    BioDrugs; 2016 Aug; 30(4):361-70. PubMed ID: 27311938
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Severe eosinophilic asthma: from the pathogenic role of interleukin-5 to the therapeutic action of mepolizumab.
    Pelaia C; Vatrella A; Busceti MT; Gallelli L; Terracciano R; Savino R; Pelaia G
    Drug Des Devel Ther; 2017; 11():3137-3144. PubMed ID: 29133975
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical efficacy and safety of mepolizumab (SB-240563), a humanized monoclonal antibody to IL-5, in cynomolgus monkeys.
    Hart TK; Cook RM; Zia-Amirhosseini P; Minthorn E; Sellers TS; Maleeff BE; Eustis S; Schwartz LW; Tsui P; Appelbaum ER; Martin EC; Bugelski PJ; Herzyk DJ
    J Allergy Clin Immunol; 2001 Aug; 108(2):250-7. PubMed ID: 11496242
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessing the value of mepolizumab for severe eosinophilic asthma: a cost-effectiveness analysis.
    Whittington MD; McQueen RB; Ollendorf DA; Tice JA; Chapman RH; Pearson SD; Campbell JD
    Ann Allergy Asthma Immunol; 2017 Feb; 118(2):220-225. PubMed ID: 27923549
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies.
    Ortega HG; Yancey SW; Mayer B; Gunsoy NB; Keene ON; Bleecker ER; Brightling CE; Pavord ID
    Lancet Respir Med; 2016 Jul; 4(7):549-556. PubMed ID: 27177493
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The safety of mepolizumab for the treatment of asthma.
    Leung E; Al Efraij K; FitzGerald JM
    Expert Opin Drug Saf; 2017 Mar; 16(3):397-404. PubMed ID: 28116937
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic drug evaluation of mepolizumab for the treatment of severe asthma associated with persistent eosinophilic inflammation in adults.
    Kallur L; Gonzalez-Estrada A; Eidelman F; Dimov V
    Expert Opin Drug Metab Toxicol; 2017 Dec; 13(12):1275-1280. PubMed ID: 29157020
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Asthma: how does mepolizumab affect exacerbations and need for steroids? Mepolizumab is a new therapeutic option in severe asthma [corrected]].
    Taube C
    Dtsch Med Wochenschr; 2014 Nov; 139(47):2380. PubMed ID: 25390624
    [No Abstract]   [Full Text] [Related]  

  • 15. Mepolizumab: First Global Approval.
    Keating GM
    Drugs; 2015 Dec; 75(18):2163-9. PubMed ID: 26603873
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway.
    Flood-Page PT; Menzies-Gow AN; Kay AB; Robinson DS
    Am J Respir Crit Care Med; 2003 Jan; 167(2):199-204. PubMed ID: 12406833
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma.
    Flood-Page P; Swenson C; Faiferman I; Matthews J; Williams M; Brannick L; Robinson D; Wenzel S; Busse W; Hansel TT; Barnes NC;
    Am J Respir Crit Care Med; 2007 Dec; 176(11):1062-71. PubMed ID: 17872493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mepolizumab Attenuates Airway Eosinophil Numbers, but Not Their Functional Phenotype, in Asthma.
    Kelly EA; Esnault S; Liu LY; Evans MD; Johansson MW; Mathur S; Mosher DF; Denlinger LC; Jarjour NN
    Am J Respir Crit Care Med; 2017 Dec; 196(11):1385-1395. PubMed ID: 28862877
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of local eosinophilopoietic processes in the development of airway eosinophilia in prednisone-dependent severe asthma.
    Sehmi R; Smith SG; Kjarsgaard M; Radford K; Boulet LP; Lemiere C; Prazma CM; Ortega H; Martin JG; Nair P
    Clin Exp Allergy; 2016 Jun; 46(6):793-802. PubMed ID: 26685004
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glucocorticoids and mepolizumab in eosinophilic asthma.
    Bel EH; Ortega HG; Pavord ID
    N Engl J Med; 2014 Dec; 371(25):2434. PubMed ID: 25517711
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.